KMT2A: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
'''KMT2A''' (Lysine Methyltransferase 2A), formerly known as '''MLL''' (Mixed-Lineage Leukemia), is a gene located on chromosome 11q23 that plays a critical role in the regulation of gene expression through histone modification. This gene is particularly significant in the context of developmental processes and hematopoiesis. Mutations and translocations involving the KMT2A gene are closely associated with various types of leukemia and other hematologic malignancies.
= KMT2A =


==Function==
[[File:9aaTADs_in_the_E_protein_family.jpg|thumb|right|300px|Structure of 9aaTADs in the E protein family, relevant to KMT2A function.]]
The KMT2A gene encodes a protein that is a member of the SET domain methyltransferase family. This protein functions as a histone methyltransferase that specifically mono-, di-, and trimethylates 'Lys-4' of histone H3. The methylation of histone H3 at Lys-4 (H3K4me) is a key epigenetic modification associated with gene activation. By modifying chromatin structure, KMT2A plays a pivotal role in the transcriptional regulation of genes involved in embryonic development and hematopoiesis.


==Clinical Significance==
'''KMT2A''', also known as '''lysine methyltransferase 2A''', is a [[gene]] that encodes a protein involved in the regulation of [[gene expression]] through [[histone modification]]. This gene is located on [[chromosome 11]] in humans and is a member of the [[SET domain]] family of proteins, which are known for their role in [[epigenetic]] regulation.
Alterations in the KMT2A gene, including point mutations, partial tandem duplications, and chromosomal translocations, are implicated in the pathogenesis of several hematological malignancies. The most common alteration is the KMT2A rearrangement, which occurs through translocations with various partner genes. These translocations result in the production of fusion proteins that possess altered epigenetic regulatory functions, contributing to leukemogenesis.


===Leukemia===
== Function ==
KMT2A rearrangements are most frequently observed in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In particular, the t(4;11)(q21;q23) translocation involving the KMT2A and AFF1 genes is a hallmark of infant ALL. These genetic alterations disrupt normal hematopoiesis and lead to the uncontrolled proliferation of leukemic cells.
KMT2A is a [[histone methyltransferase]] that specifically methylates [[histone H3]] at lysine 4 (H3K4). This modification is associated with [[transcriptional activation]] and is crucial for the regulation of [[gene expression]] during [[development]] and [[cell differentiation]]. The protein encoded by KMT2A contains several important domains, including a [[SET domain]], which is responsible for its methyltransferase activity, and [[PHD finger]] domains, which are involved in recognizing specific histone modifications.


==Diagnosis and Prognosis==
== Clinical significance ==
The detection of KMT2A rearrangements is crucial for the diagnosis and risk stratification of leukemia. Various molecular biology techniques, including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS), are employed to identify KMT2A gene alterations. Patients with KMT2A-rearranged leukemia often have a poor prognosis and require aggressive treatment strategies.
Mutations and rearrangements involving the KMT2A gene are implicated in various forms of [[leukemia]], particularly [[acute lymphoblastic leukemia]] (ALL) and [[acute myeloid leukemia]] (AML). These rearrangements often result in the formation of [[fusion proteins]] that disrupt normal gene regulation and contribute to the development of cancer.


==Treatment==
== Structure ==
The treatment of KMT2A-rearranged leukemia typically involves intensive chemotherapy, targeted therapy, and, in some cases, hematopoietic stem cell transplantation. Recent advances in targeted therapy have led to the development of small molecule inhibitors that specifically target the enzymatic activity of KMT2A fusion proteins, offering a promising therapeutic approach for patients with this genetic alteration.
[[File:Piskacek_Figures_v9b.jpg|thumb|left|300px|Diagram illustrating the structural domains of KMT2A.]]
The KMT2A protein is a large, multi-domain protein that includes several [[zinc finger]] motifs, [[AT hooks]], and a [[SET domain]]. The presence of these domains allows KMT2A to interact with [[DNA]] and other [[chromatin]] components, facilitating its role in modifying chromatin structure and regulating gene expression.


==Research Directions==
== Interactions ==
Ongoing research aims to better understand the molecular mechanisms by which KMT2A alterations contribute to leukemogenesis and to develop more effective and less toxic therapeutic strategies. The identification of novel therapeutic targets and the design of targeted therapies hold the potential to improve outcomes for patients with KMT2A-rearranged leukemia.
KMT2A interacts with a variety of other proteins to form a [[protein complex]] that is essential for its function in histone methylation. These interactions include binding with [[WDR5]], [[ASH2L]], and [[RBBP5]], which are components of the [[COMPASS complex]]. This complex is responsible for the trimethylation of H3K4, a key marker of active chromatin.


[[Category:Genes]]
== Related pages ==
[[Category:Oncology]]
* [[Histone methylation]]
[[Category:Hematology]]
* [[Epigenetics]]
* [[Chromatin]]
* [[Leukemia]]
* [[Gene expression]]


{{DEFAULTSORT:Kmt2a}}
[[Category:Genes on human chromosome 11]]
{{Gene-stub}}
[[Category:Epigenetics]]
{{Medicine-stub}}
[[Category:Histone-modifying enzymes]]
== KMT2A ==
<gallery>
File:KMT2A.jpg|KMT2A protein structure
File:9aaTADs_in_the_E_protein_family.jpg|9aaTADs in the E protein family
File:Piskacek_Figures_v9b.jpg|Piskacek Figures version 9b
File:Gray626.png|Gray's Anatomy illustration 626
</gallery>

Latest revision as of 14:11, 21 February 2025

KMT2A[edit]

Structure of 9aaTADs in the E protein family, relevant to KMT2A function.

KMT2A, also known as lysine methyltransferase 2A, is a gene that encodes a protein involved in the regulation of gene expression through histone modification. This gene is located on chromosome 11 in humans and is a member of the SET domain family of proteins, which are known for their role in epigenetic regulation.

Function[edit]

KMT2A is a histone methyltransferase that specifically methylates histone H3 at lysine 4 (H3K4). This modification is associated with transcriptional activation and is crucial for the regulation of gene expression during development and cell differentiation. The protein encoded by KMT2A contains several important domains, including a SET domain, which is responsible for its methyltransferase activity, and PHD finger domains, which are involved in recognizing specific histone modifications.

Clinical significance[edit]

Mutations and rearrangements involving the KMT2A gene are implicated in various forms of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These rearrangements often result in the formation of fusion proteins that disrupt normal gene regulation and contribute to the development of cancer.

Structure[edit]

Diagram illustrating the structural domains of KMT2A.

The KMT2A protein is a large, multi-domain protein that includes several zinc finger motifs, AT hooks, and a SET domain. The presence of these domains allows KMT2A to interact with DNA and other chromatin components, facilitating its role in modifying chromatin structure and regulating gene expression.

Interactions[edit]

KMT2A interacts with a variety of other proteins to form a protein complex that is essential for its function in histone methylation. These interactions include binding with WDR5, ASH2L, and RBBP5, which are components of the COMPASS complex. This complex is responsible for the trimethylation of H3K4, a key marker of active chromatin.

Related pages[edit]